{"organizations": [], "uuid": "a089d08ba571192244cb7c5918627a63195c22ea", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180117.html", "section_title": "Archive News &amp; Video for Wednesday, 17 Jan 2018 | Reuters.com", "url": "https://www.reuters.com/article/buzz-onconova-panel-recommends-co-to-con/buzz-onconova-panel-recommends-co-to-continue-late-stage-blood-cancer-drug-study-idUSL3N1PC4A9", "country": "US", "domain_rank": 408, "title": "BUZZ-Onconova: Panel recommends co to continue late-stage blood cancer drug study", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.061, "site_type": "news", "published": "2018-01-17T23:59:00.000+02:00", "replies_count": 0, "uuid": "a089d08ba571192244cb7c5918627a63195c22ea"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/buzz-onconova-panel-recommends-co-to-con/buzz-onconova-panel-recommends-co-to-continue-late-stage-blood-cancer-drug-study-idUSL3N1PC4A9", "ord_in_thread": 0, "title": "BUZZ-Onconova: Panel recommends co to continue late-stage blood cancer drug study", "locations": [], "entities": {"persons": [{"name": "akankshita mukhopadhyay", "sentiment": "none"}], "locations": [{"name": "bengaluru", "sentiment": "none"}], "organizations": []}, "highlightText": "", "language": "english", "persons": [], "text": "** Cancer drug developer’s shares up as much as 53.16 pct to $2.67 - biggest intraday pct gain in more than 3 months\n** Says an independent data monitoring committee (IMDC) recommended co to continue its late-stage study of its lead drug, rigosertib, in patients with higher-risk myelodysplastic syndromes\n** IMDC recommends co to increase enrollment by adding 135 patients to the original target to reach a total enrollment of 360 patients\n** Myelodysplastic syndromes are a group of cancers in which immature blood cells in the bone marrow do not mature or become healthy blood cells\n** In 2014, rigosertib failed to improve overall survival in late-stage trial in high risk myelodysplastic syndrome patients\n** Up to Tuesday’s close, stock had fallen about 36 pct in the past twelve months (Reporting by Akankshita Mukhopadhyay in Bengaluru)\n ", "external_links": ["http://thomsonreuters.com/en/about-us/trust-principles.html"], "published": "2018-01-17T23:59:00.000+02:00", "crawled": "2018-01-18T16:06:51.009+02:00", "highlightTitle": ""}